Author： Zohar Sarah Chevret Sylvie
Publisher： Taylor & Francis Ltd
ISSN： 1054-3406
Source： Journal of Biopharmaceutical Statistics, Vol.17, Iss.6, 2007-11, pp. : 1071-1083
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Cancer dose-finding trials aim at assessing the maximum tolerated dose (MTD) of a new treatment or combination. Owing to ethical constraint, they are based on adaptive designs, sequentially allocating patients to increased doses on the basis of previous responses. More recently, the concept of MTD has been extended to the largest concept of most successful or most desirable dose, based on efficacy criterion under toxicity restrictions. The aim of this paper is to present three main approaches proposed to estimate such a dose, in the setting of Phase I/II trials. Two case-studies allow to illustrate these new approaches.
Access to resources
Recommend
